Gilead turbocharges production of COVID-19 hopeful remdesivir
With the coming Oil & Gas Asia Exhibition in Pakistan, ECHEMI rolls out a new bulk purchasing activity for its new and old customers. This activity will be valid before March 16 when the exhibition come to the end. The more you buy, the more money you will save.
How to join this bulk purchasing?
You can enjoy the most favorable prices via three steps:
First, you should come to the home page of ECHEMI, then you can see the the following page:
Second, input your demand and submit the inquiry.
Third, ECHEMI will give you a reply within 1 working day after receiving your inquiry.
Opportunity knocks but once! Come on, seize this opportunity right now!
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-09
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Gilead Sciences Reports Q3 2023 Financial Results
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
FDA Lifts Clinical Hold on Gilead's HIV Drug Lenacapavir
-
COVID-19 Drug Remdesivir Approved for Infants And Young Children
-
Gilead's CD47 Monoclonal Antibody Clinical Trial Was 'Unblocked' By FDA
-
After Remdesivir, where is the next hope?
-
Gilead: Remdesivir sold $1.93 billion in Q4
-
Gilead: Remdesivir sold $1.93 billion in Q4
-
The most noteworthy new 'blockbuster' drugs in 2020
-
Sinopharm and Gilead announce cooperation
Recommend Reading
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
September Pure Benzene Market Overview (September 1–30, 2025)
-
The Cost of 2,000 Jobs: How ExxonMobil Uses Layoffs to Announce a Global Chemical Map Reshuffle
-
“Changing the Captain at Sea”: Hempel’s CEO Departs to Run a Ferry Giant—This Isn’t a Resignation Notice, It’s an Industry Stress Map
-
China Fuel Oil 180CST Market Trends Remain Stable Through Late September
-
He Spent 40 Years at Nestlé—Then Was “Cleared Out” Days After Becoming CEO: This Isn’t a Scandal, It’s Capital’s Coldest Face